試す金 - 無料

BioSpectrum Asia - BioSpectrum Asia May 2025

Magzter GOLDで無制限に

読む BioSpectrum Asia 9,500以上の雑誌や新聞を1回の定期購読で購読できます

カタログを見る

1ヶ月

$14.99

1年 $149.99

$149.99

$12/month

(OR)

BioSpectrum Asiaのみを購読する

贈り物 BioSpectrum Asia

いつでもキャンセルできます。

(義務なし) ⓘ

定期購読にご満足いただけない場合は、定期購読開始日から 7 日以内に help@magzter.com までメールをお送りいただければ、全額返金いたします。質問は一切ありません。お約束します! (注: 単号購入には適用されません)

デジタルサブスクリプション

即時アクセス ⓘ

今すぐ購読すると、Magzter の Web サイト、iOS、Android、Amazon アプリですぐに読み始めることができます。

安全性を確認済み

支払い ⓘ

Magzter は Authorize.Net の認定販売業者です。詳細はこちら

この号では

APAC Vaccine Powerhouses Flex Capacity & Quality Muscle Asia is the epicentre of global vaccine manufacturing, with India and China together supplying over a billion doses annually. Now, emerging players like South Korea, Singapore, and Australia are stepping up, investing in next-gen platforms and expanding capacity to meet global demand. Let’s map the manufacturing footprint of Asia’s leading vaccine manufacturers, tracking their current capacity, expansion plans, and the strategic shifts that are transforming the region into a global vaccine production hub.

TARIFF WAR PUTS PHARMA IN CROSSHAIRS

While several other countries in the world have probably heaved a sigh of relief, though, for three months, China has launched an onslaught on the US in the bitter trade tariff war.

2 mins

China gives nod to first haemophilia B gene therapy

Belief BioMed (BBM) and Takeda China have jointly announced that BBM-H901 (Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with moderate to severe haemophilia B (congenital coagulation factor IX deficiency).

1 mins

Korea and Romania to strengthen cooperation in healthcare

The Ministry of Health and Welfare, South Korea recently held a bilateral meeting with Alexandru Rafila, Minister of Health of Romania.

1 mins

Apollomics, LaunXP ink $50 M deal for NSCLC treatment in Asia

US-based Apollomics Inc., and Taiwan-based LaunXP International Co., an affiliate of LaunXP Biomedical Co., have entered into an agreement for the development and commercialisation in Asia (excluding mainland China, Hong Kong and Macau) of vebreltinib, Apollomics' proprietary c-Met inhibitor, in combination with an EGFR inhibitor (EGFRI) for the treatment of non-small cell lung cancer (NSCLC).

1 mins

AstraZeneca invests $2.5 B to establish sixth global strategic R&D centre in China

British pharmaceutical company AstraZeneca has announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance life sciences in China.

1 mins

commercial Shionogi inks deal for Cefiderocol in Australia and New Zealand

Japanese pharmaceutical company Shionogi & Co. has entered into an exclusive licensing agreement with Link Medical Products, a part of Clinigen, the global specialty pharmaceutical services group, for the development and commercialisation of cefiderocol in Australia and New Zealand.

1 mins

Saisei Ventures introduces Executive Fellows Programme for Japan's biotech leadership pipeline

Saisei Ventures, a leading venture investment firm focused on advancing Japanese biotechnology and therapeutic innovations, has announced the launch of its Executive Fellows Programme, a structured mentorship initiative designed to strengthen the next generation of biotech entrepreneurs and executives in Japan.

1 mins

Singapore expands startup hub in Tokyo to propel deep tech innovation

NUS Enterprise, the entrepreneurial arm of the National University of Singapore (NUS), is expanding its presence in Japan with the launch of its second BLOCK71 office in Tokyo.

1 mins

GSK joins hands with Korea's ABL Bio for treatment of neurodegenerative diseases

South Korea-based startup ABL Bio Inc. has announced a worldwide licensing agreement enabling GlaxoSmith-Kline Pharmaceuticals (GSK) to develop novel medicines for neurodegenerative diseases by utilising ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B.

1 mins

Africa CDC unveils strategic plan to transform health financing

With external health aid to Africa expected to plunge by 70 per cent between 2021 and 2025, the Africa Centres for Disease Control and Prevention (Africa CDC) has launched a continent-wide strategy to radically transform how health systems are financed, putting African resources at the centre of African health.

1 mins

Swiss awards 5-Year grant to FIND for innovative malaria testing

The FIND Board has received notice of an award from the Swiss government of a grant to develop an innovative point-of-care rapid diagnostic test (RDT) for P. vivax malaria.

1 mins

APAC Vaccine Powerhouses Flex Capacity & Quality Muscle

Asia is the epicentre of global vaccine manufacturing, with India and China together supplying over a billion doses annually. Now, emerging players like South Korea, Singapore, and Australia are stepping up, investing in next-gen platforms and expanding capacity to meet global demand. Let's map the manufacturing footprint of Asia's leading vaccine manufacturers, tracking their current capacity, expansion plans, and the strategic shifts that are transforming the region into a global vaccine production hub.

10+ mins

"Asia-Pacific region has firmly established itself as a global vaccine export powerhouse"

Suchitra Ella, Managing Director of Bharat Biotech, India delves into the evolution of vaccine manufacturing capacity in the Asia-Pacific region over the past decade and explores key lessons learned from the COVID-19 pandemic that will shape the future of vaccine production and distribution. Edited excerpts:

4 mins

Medtech education in APAC keeping pace with innovation

As medical devices grow smarter and more interconnected using AI, robotics and virtual reality, the need to train professionals is growing urgently. To position itself as a global powerhouse for medical technology, Asia Pacific (APAC) countries such as China, Japan, Korea, India, Singapore, Vietnam, Thailand, Taiwan are ramping up medtech education initiatives, recognising the critical role that talent pipelines, partnerships, and digital innovation play in advancing their healthcare economies. Let's take a closer look at the new initiatives being taken up by the APAC region for strengthening the medtech education sector amidst many challenges and opportunities.

7 mins

The Rise of K-Biotech

After K-pop, K-dramas, and K-beauty, South Korea is now turning its focus to biotechnology. Through a series of government initiatives and industry investments, the country is working to position itself as a major player in the global biotech sector. From manufacturing capacity to research and development, Korea is laying the groundwork to become a significant force in the biotech industry.

7 mins

"South Korea is rapidly emerging as a global biotech powerhouse"

Orum Therapeutics debuted on the Korea Exchange (KOSDAQ) on February 14, 2025, raising ₩50 billion in South Korea's first biopharma IPO of the year. With a focus on targeted protein degraders for cancer treatment, CEO S J Lee outlines how Orum is advancing and positioning itself at the forefront of oncology innovation. Edited excerpts;

2 mins

"The biosimilar developers are eagerly awaiting revised CDSCO regulations that might lead to simplification of the development pathway for biosimilars"

In an interaction with BioSpectrum, I Dr Dr Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council (BIRAC), India reflects on the evolution of India's biosimilars sector and shares his insights on the country's growing role in the global biosimilars landscape over the next decade.

4 mins

Biomarkers in Kidney Health: Enhancing Early Detection and Treatments

Emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) have shown great potential in the early diagnosis of kidney injury. These biomarkers are extremely sensitive indicators of tubular injury, and they can detect renal damage at stages when conventional markers are still within normal ranges. While these novel biomarkers have high sensitivity and specificity, incorporating them into ordinary clinical practice raises several problems. Despite its potential, more study is needed to validate these biomarkers in large-scale, long-term clinical studies.

4 mins

Medical Device Classification and FDA Approval: What Startups Need to Know

For many innovators, the United States represents a key market, being the world's largest for medical devices. However, entering the US market requires navigating the US Food and Drug Administration's (FDA) stringent regulatory landscape, where accurate device classification is crucial. To assist innovators, the Regulatory Information and Facilitation Center (RIFC) at Venture Center, Pune has released a whitepaper early this year that offers practical insights, featuring examples of devices developed by Venture Center-supported startups to illustrate how medical devices are categorised based on risk.

3 mins

Rise of Chinese companies in global medtech sector

The global medical technology (medtech) sector is undergoing a profound transformation, driven significantly by the rapid and strategic ascent of Chinese companies. The long-held narrative of China solely as a manufacturer of low-cost goods is dangerously outdated. Today, Chinese medtech firms are not merely competing on the global stage; they are increasingly setting the pace in innovation, enhancing product quality, and expanding their international reach. This shift necessitates a strategic reassessment by established players and presents both significant opportunities and complex challenges for the entire healthcare ecosystem. This article dissects the key drivers behind China's medtech surge, analyses their global expansion strategies, evaluates their competitive positioning, and provides an outlook on the future landscape.

4 mins

University of Hyderabad and Flinders University cement partnership in healthcare

The University of Hyderabad (UoH), India and Australia's Flinders University have entered into a landmark strategic partnership, formalised through the signing of a Memorandum of Understanding (MoU).

1 mins

Australia lays focus on nanotechnology to improve odds in treating aggressive breast cancers

Australia's University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer.

1 mins

Thermo Fisher Scientific introduces Krios 5 Cryo-Transmission Electron Microscope

Thermo Fisher Scientific has introduced the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope (TEM). This next-generation, atomic-resolution platform leverages enhanced optics and AI-enabled automation to study molecular structures and interactions at a throughput and fidelity that was previously unattainable.

1 mins

すべてのストーリーを読む BioSpectrum Asia

BioSpectrum Asia Description:

出版社: MM-Activ-Sci-Tech-Communication

カテゴリ: Business

言語: English

頻度: Monthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.

* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.

* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.

* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.

* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.